Clinical Trial Update: A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 study evaluated switching adults with Type 2 diabetes from daily insulin glargine to once-weekly insulin icodec to improve glycemic control; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (Lantus) (insulin glargine)
• Insulin Icodec (insulin icodec)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Type 2 | Phase 3 | Status: COMPLETED